Page 28 - Boxed Warning News Today

The FDA has approved the first T-cell–engaging bispecific antibody, epcoritamab-bysp (Epkinly), for the treatment of adult patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma, after 2 or more lines of systemic therapies.

The FDA has approved Epkinly™ (epcoritamab-bysp) for the treatment of relapsed or refractory diffuse large B-cell lymphoma, not otherwise specified.

The FDA approval of Epkinly also includes a subset of patients with indolent lymphoma-related DLBCL and those with high-grade B-cell lymphoma after two or more systemic therapies.

Approval for the T-cell–engaging bispecific antibody came today from the FDA.

The FDA has approved Lexapro (escitalopram) for the treatment of generalized anxiety disorder in pediatric patients 7 years of age and older.

The FDA is requiring updated warnings for prescription stimulants to ensure the safe use of these medications.

Eight presentations at ASCO and EHA 2023 Annual Meetings showcase continued leadership in CAR-T cell therapy research for patients with multiple myeloma across various clinical settings First... | May 16, 2023

? Clinical and Patient Experience Research Delivers Insights into Treatment for People Living with Schizophrenia or Bipolar I Disorder ? DUBLIN, May 16, 2023 /PRNewswire/ -- Alkermes

/PRNewswire/ -- Shorla Oncology (Shorla), a U.S.-Ireland pharmaceutical company, and EVERSANA®, a leading provider of commercialization services to the life...

For a class of drugs used for narcolepsy, the FDA is requiring updates to the Boxed Warning to address concerns of abuse and addiction.